Clinical TrialsSearch results
Number of results: 265
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Recruiting
- Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
- Paroxysmal Nocturnal Hemoglobinuria
- Suzuki Kazuyuki
- 2021-12-17
Recruiting
- A study to evaluate the efficacy and safety of rozanolixizumab in adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD)
- Myelin oligodendrocyte glycoprotein (MOG)antibody-associated disease (MOG-AD)
- MATSUO TETSUO
- 2021-11-24
Recruiting
- Safety study of artificial neural connection in stroke
- Brain infarction, hemorrhage
- Kikuchi Naohisa
- 2021-11-19
Recruiting
- Program of Angiotensin-Neprilysin Inhibition in Admitted Patients with Worsening Heart Failur
- Worsening heart failure with both signs of congestion and symptoms of heart failure
- Node Koichi
- 2021-11-15
Recruiting
- Development of a questionnaire to evaluate the risk of chronic postsurgical pain
- Chronic Pain
- NAKANO YUKO
- 2021-10-29
Recruiting
- Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
- ASCVD, CKD and systemic inflammation
- Miyazaki Daisuke
- 2021-09-07
Recruiting
- An Exploratory Study of FHM-001 in Patients with Depression
- depression (DSM-5)* (single episode or recurrent)
- Furukawa Toshiaki
- 2021-08-19
Recruiting
- Pivotal study of danicopan as add-on therapy to a C5 inhibitor (eculizumab or ravulizumab) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have Clinically Evident EVH
- Paroxysmal Nocturnal Hemoglobinuria
- Kamata Takeo
- 2021-06-28
Other
- Effect of dotinurad in hyperuricemia with hypertension (DIANA)
- hyperuricemia complicated by hypertension
- Node Koichi
- 2021-06-24
Recruiting
- A phase II study of combination of radiotherapy and Atezolizumab/nab-paclitaxel
for inoperable or recurrent PD-L1 positive triple negative breast
cancer
- inoperable or recurrent PD-L1 positive triple negative breast cancer
- Suzuki Yoshiyuki
- 2021-06-04